We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Medical Implant Coating Lowers Rejection Rates

By HospiMedica International staff writers
Posted on 18 Feb 2010
A novel "smart coating” for surgical implants bonds more closely with bone and wards off infection, claims a new study. More...


Researchers at North Carolina State University (Raleigh, USA) and Oak Ridge National Laboratory (Oak Ridge, TN, USA) developed a series of functionally graded hydroxyapatite (FGHA) coatings that can be applied on to titanium substrates using ion beam-assisted deposition. The smart coatings mitigate the risk of implant rejection by fostering bone growth into the implant by creating a crystalline layer next to the implant, as well as a mostly amorphous outer layer that touches the surrounding bone. The amorphous layer dissolves over time, releasing calcium and phosphate, which encourages bone growth. The researchers also incorporated silver nanoparticles --using various percentages of silver--throughout the coating to ward off infections, which act as antimicrobial agents while the amorphous layer dissolves. This not only limits the amount of antibiotics the patients will need following surgery, but provides protection from infection at the implant site; moreover, the silver is released more quickly right after surgery, when there is more risk of infection, due to the faster dissolution of the amorphous layer of the coating.

The analysis of the coating's cross-section using transmission electron microscopy (TEM) and scanning transmission electron microscopy equipped with energy dispersive X-ray spectroscopy showed a decreased crystallinity as well as a distribution of nanoscale (10-50 nm) silver particles from the coating-substrate interface to the top surface of the implant. Both X-ray diffraction and fast Fourier transforms on high-resolution TEM images revealed the presence of hydroxyapatite within the coatings. The study was published in the January 2010 issue of Acta BioMaterialia.

"We call it a smart coating because we can tailor the rate at which the amorphous layer dissolves to match the bone growth rate of each patient,” said coauthor Afsaneh Rabiei, Ph.D., an associate professor of mechanical and aerospace engineering at North Carolina State University. "The bone grows into the coating as the amorphous layer dissolves, resulting in improved bonding, or osseointegration. This bonding also makes the implant more functional, because the bonding helps ensure that the bone and the implant do a better job of sharing the load.”

Related Links:

North Carolina State University
Oak Ridge National Laboratory



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.